Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada

LAVAL, QC, Feb. 23, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in medical aesthetics, today announced the launch of the Clear + Brilliant® Touch laser in Canada. The device was approved by Health Canada on May 20, 2025, marking an important milestone as demand for non‑invasive skin rejuvenation treatments continues to grow across Canada.

PRNewsWire • Feb 23, 2026

Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now?

IRWD has the edge over BHC with high Linzess demand and upbeat 2026 revenue outlook offsetting pipeline and pricing risks.

Zacks Investment Research • Feb 20, 2026

Bausch + Lomb Q4 Earnings Review: Still A Buy, With Some Caveats

Bausch + Lomb delivered 7% constant currency Q4 revenue growth and 27% adjusted EBITDA growth, reinforcing strong operating leverage. I maintain my Buy rating on BLCO, citing robust revenue momentum, promising product pipelines, and a path toward improved profitability and valuation. BLCO targets 5–7% annual revenue growth through 2028, driven by innovation in contact lenses, dry eye therapies, and premium intraocular lenses.

Seeking Alpha • Feb 19, 2026

BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth

Bausch stock slips as Q4 EPS misses despite 9% revenue growth, strong Salix and Bausch + Lomb gains, and an upbeat 2026 sales outlook.

Zacks Investment Research • Feb 19, 2026

Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres

The only FDA‑approved locally applied antibiotic used with scaling and root planing (SRP) marks a quarter‑century of clinical use LAVAL, QC, Feb. 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its dental products business, OraPharma, today announced the 25th anniversary milestone of ARESTIN® (minocycline HCl) Microspheres, 1 mg, a locally administered antibiotic used as an adjunct to scaling and root planing (SRP) for the reduction of pocket depth in adult patients with periodontitis. ARESTIN is supported by over two decades of clinical experience and remains the only Food and Drug Administration (FDA) approved locally applied antibiotic for this use.

PRNewsWire • Feb 19, 2026

How Bausch Health's Turnaround Progressed In Q4 2025

How Bausch Health's Turnaround Progressed In Q4 2025

Seeking Alpha • Feb 19, 2026

Bausch Health Companies Inc. (BHC) Q4 2025 Earnings Call Transcript

Bausch Health Companies Inc. (BHC) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 19, 2026

BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

Fourth Quarter Consolidated Revenues of $2.80 billion, up 9% on a Reported basis and up 6% on an Organic (non-GAAP) 1  basis over the prior year period Full-Year Consolidated Revenues of $10.27 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basis GAAP Net Loss Attributable to Bausch Health of $112 million for the quarter and GAAP Net Income Attributable to Bausch Health of $157 million for the year Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $1.05 billion for the quarter, up 13%, and $3.54 billion for the year, up 7% BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FOURTH QUARTER AND FULL-YEAR 2025 RESULTS Delivered eleventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1, exceeding 2025 guidance on all metrics Completed the acquisition of Shibo's full‑service aesthetics distribution business in China on December 1, 2025 Executed a $1.7 billion debt exchange offer during the fourth quarter and $9.6 billion in total refinancing for the Full-Year 2025, extending near- and medium-term maturities Generated $362 million in Adjusted Cash Flow from Operations (non-GAAP)1 in the fourth quarter and $1.2 billion for the Full-Year 2025 LAVAL, QC, Feb. 18, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" the "Company," "we" or "our") today announced its fourth quarter and full-year 2025 financial results and other key updates for the quarter. "The fourth quarter marks our eleventh consecutive quarter of year‑over‑year growth in Revenue and Adjusted EBITDA for Bausch Health, excluding Bausch + Lomb.

PRNewsWire • Feb 18, 2026

Bausch Health (BHC) Q4 Earnings Lag Estimates

Bausch Health (BHC) came out with quarterly earnings of $1.08 per share, missing the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $1.15 per share a year ago.

Zacks Investment Research • Feb 19, 2026

Here's What Key Metrics Tell Us About Bausch (BHC) Q4 Earnings

The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Feb 19, 2026